AI in healthcare teams

Choosing an AI scribe: questions to ask a vendor before you sign

Ask where patient data is stored and processed, whether any of it leaves Australia, how long it is kept, and whether the vendor uses it to train its models or for anything else. Then ask how the AI scribe handles consent and can be switched off, what happens after a breach or an error, how it fits your clinical software, whether you can trial it, and how you leave. The RACGP and the OAIC both expect a practice to do this due diligence and read the terms before it buys. A vendor's answers inform your decision; they do not settle your own obligations, so take the contract to your medical defence organisation or lawyer.

What is an AI scribe?

A tool that captures the conversation in a consultation and generates notes from it. The TGA's digital scribes page says digital scribes, also called AI scribes, ambient scribes or ambient voice technology, capture conversations between patients and healthcare practitioners and generate clinical notes, summaries, letters or other outputs, which may be added to patient records. It says they may use a range of software technologies, including generative AI.

Why ask an AI scribe vendor before you sign?

Because once patient information goes into an AI scribe, the terms you agreed to decide what happens to it. The OAIC's guidance on commercially available AI products says businesses should do due diligence before adopting a product, and should "carefully review the terms and settings" that will apply to its use. It also says that once personal information has been put into an AI system, it can be very difficult to track or control how it is used, and "potentially impossible to remove".

The RACGP's AI scribes page makes the same point for scribes. It advises GPs and practices to review the user agreement before purchasing, and to seek independent legal advice or consult their medical defence organisation on the security, privacy and contractual aspects. AHPRA's guidance for practitioners says practitioners should understand how data is used to retrain the AI, where it is located and how it is stored.

Questions to put to the vendor

  1. Where is our patient data stored and processed, and how is it protected? Why it matters: the RACGP says GPs should know what assurances, if any, the vendor gives on how captured data is encrypted, stored, destroyed and managed, because a breach can expose recordings, transcripts and notes. Avant's AI scribes checklist asks whether retained data is encrypted and where it is stored. A good answer: specific and in writing, naming where each kind of data is held and how it is protected, and pointing to the clause or policy that says so.
  2. Does any of our data leave Australia, even briefly? Why it matters: the RACGP says practices need to check whether scribe data will be processed or stored outside Australia. In its words, if data is processed or stored overseas "for any amount of time", vendors must ensure the country has similar privacy standards and protections to Australia's, and should give assurances that the product meets Australian legal obligations. Avant notes that sending data overseas may bring extra obligations, and points to the OAIC's Australian Privacy Principle 8 on cross-border disclosure. A good answer: names the countries involved, for processing as well as storage, and gives the written assurance the RACGP describes. The RACGP says that if a vendor cannot give such assurances, it is advisable to avoid its products.
  3. What do you keep, for how long, and can we delete it? Why it matters: audio, transcripts and draft clinical notes can all hold patient information. Avant asks whether any data is collected or retained by the provider, whether it is identifiable, whether you can access it and how long it is held. A good answer: says separately what happens to audio, transcripts and generated notes, gives the retention period for each, and explains how the practice can have data deleted.
  4. Will our data be used to train your models, or for anything else, and who else can see it? Why it matters: the RACGP says vendors might use collected data for secondary purposes such as training AI models or developing other products, and advises reading the user agreement and deciding whether any secondary use is acceptable before purchasing. The OAIC says some products have terms or settings that let the owner collect customer data for further training, and that letting the developer or a third party access personal information raises questions under Australian Privacy Principle 6. A good answer: points to the clause that covers training and other uses, says whether any third party receives data, and says whether those uses can be switched off.
  5. How does the AI scribe handle patient consent? Why it matters: AHPRA says AI transcription software "should include an explicit consent requirement as an initial step before proceeding". Avant asks whether the scribe prompts for consent at each consultation, and whether the record it produces notes that consent was obtained. A good answer: shows where the consent step sits in the workflow and what the scribe writes into the notes.
  6. How does a clinician pause or stop the scribe for one consultation? Why it matters: a patient may say no, and the consultation goes ahead without the scribe. Avant says your business continuity plan should describe how you would work without the scribe, and that this "may also apply if a patient does not consent". None of the sources this guide draws on covers stopping partway through a consultation, so ask the vendor to show you. A good answer: a demonstration of how recording is paused or stopped, and what happens to anything already captured.
  7. What happens if there is a data breach or the system fails? Why it matters: the OAIC says to consider the product's security, including searching for past security incidents and asking what measures the owner has in place to detect and protect against attacks. Avant asks whether the provider will notify you of a breach, tell you how to respond and disengage, and whether records can be recovered after a system failure. A good answer: says how and when the vendor will tell the practice about an incident, and how data is recovered after a failure.
  8. Who is responsible when the scribe gets something wrong? Why it matters: the RACGP says GPs using AI scribes are responsible for making sure their patients' health records are accurate, and AHPRA says the practitioner is responsible for checking records created with generative AI. Avant asks whether the agreement has disclaimers, warranties or indemnity clauses that shift responsibility to the user. It warns that agreeing to a broad indemnity clause may have implications for its members' insurance, and suggests seeking advice first. A good answer: points you to every clause on errors, warranties and indemnity, so you can take them to your medical defence organisation. This guide does not say who is liable.
  9. What is each function intended to do, and how will you tell us when an update changes it? Why it matters: the TGA's digital scribes page says not all digital scribes are medical devices, and that it depends on what the product is intended to do. It says intended purpose is shown by the product's labelling, instructions, advertising and website, and that an update adding a function with a therapeutic use makes the product a medical device. Avant asks how the scribe will be updated, and whether updates are automatic and included in the agreement. A good answer: a written description of what each function is intended to do, and how the practice is told about changes before they arrive.
  10. How does it fit our clinical software and the way we work? Why it matters: the RACGP suggests checking how a scribe integrates with current clinical information and workflows. It says that if a scribe is not fully integrated into your general practice software, observations, measurements and examination findings may need to be added into the right fields by hand. Avant's AI medical scribe FAQ says some scribes integrate with practice platforms and file the notes they generate into patient records. A good answer: a demonstration in your own clinical software showing where the clinical notes go and what still has to be entered by hand.
  11. Can we trial it before we commit, and what will we pay after? Why it matters: AHPRA says all tools and software should be tested by the user or organisation to make sure they are fit for purpose before use in clinical practice. The RACGP suggests taking advantage of any free trial period to test how a scribe works, including the clarity and accuracy of its output. Avant says to check what you will get, for what price and over what time period. A good answer: the trial terms in writing, including what happens to data entered during the trial, and how pricing is structured once it ends.
  12. The vendor says the product is "HIPAA compliant". How does it handle our data under Australian privacy law? Why it matters: HIPAA, the Health Insurance Portability and Accountability Act of 1996, is a United States Act of Congress. In Australia, the RACGP says a product's terms and conditions, terms of service or privacy policy will usually indicate whether data is collected and handled in accordance with the Privacy Act 1988 and the Australian Privacy Principles. A good answer: points to where its terms or privacy policy say how it handles your data under that law, consistent with its answers to questions 1 to 4. This guide does not say whether any product meets either law.
  13. How do we leave, and what happens to our data when we do? Why it matters: Avant asks how much notice you must give to end the agreement and whether there are penalties. It also asks whether you can access historical data, and information about how the AI worked at a particular time, which you may need after a system failure or a later claim or complaint. A good answer: the notice period and any exit costs, whether you can take a copy of your data and in what form, what the vendor does with your data after you leave, and how long you can still get at the history you need.

The OAIC's own checklist for selecting an AI product asks similar questions about security, the operating environment and developer access to your inputs. You can use it alongside this list.

What does a good answer look like?

Specific, in writing, and traceable to the contract. The RACGP says information on how data is handled can usually be found in the product's terms and conditions, terms of service or privacy policy. Avant says that if the information is not available, ask the provider directly, and that if you are not comfortable with the answers, you may wish to explore other options.

A vendor's answer does not make your practice's use of the scribe meet its obligations. The OAIC says developers' safeguards "will not be foolproof", and that a business will need to put in place its own processes to make sure its use of AI meets its privacy obligations. Keep the answers with your decision record, and note any you could not get.

Who answers the liability question?

Your medical defence organisation or lawyer, not the vendor and not this guide. AHPRA's guidance says practitioners should hold appropriate professional indemnity insurance for all aspects of their practice, and consult their provider if they are unsure whether the AI tools they use are covered. The RACGP says practices should seek independent legal advice or consult their medical defence organisation on the contractual aspects of a scribe. Take the vendor's answers to question 8, and the agreement itself, to that conversation.

Does the vendor's answer tell us whether an AI scribe is a medical device?

Not on its own. The TGA says whether a scribe is regulated as a medical device depends on what it is intended to do, and that intended purpose is judged from how the product is described and presented. It also says a general disclaimer is not enough to show a scribe is not a medical device if it makes medical claims or has features consistent with one. Question 9 helps you understand what the vendor says each function does. Whether that makes a particular scribe a medical device is a question for the TGA, and this guide does not classify any product.

What happens after we choose an AI scribe?

The questions keep going. The OAIC says due diligence should not be "set and forget", and that the product's performance, staff training and monitoring should be reviewed across its whole life. The RACGP says the implementation of AI tools requires ongoing due diligence, including monitoring a scribe's performance. Avant suggests appointing a person in the practice to monitor use of the scribe and make sure updates are actioned.

The vendor's answers on consent also shape how the consent step works in each consultation. For the wider picture, see the AI in healthcare teams hub.

This page is general information, not legal advice. It summarises guidance from the RACGP, the OAIC, AHPRA, the TGA and Avant, names no product, and does not say whether any scribe, vendor or contract meets your obligations. Confirm your obligations with your medical defence organisation, and with your lawyer or privacy adviser where the question is about the contract or privacy law.

How we help: Make informed decisions about AI

Sources

  1. RACGP, Artificial intelligence (AI) scribes (Header 29 Jun 2026; publication info: first published Aug 2024, updated Oct 2025)
  2. OAIC, Guidance on privacy and the use of commercially available AI products (Published 21 Oct 2024; updated 17 Jan 2025)
  3. AHPRA, Meeting your professional obligations when using Artificial Intelligence in healthcare (Page reviewed 22 Aug 2024)
  4. Avant, AI scribes: a checklist of things to consider (13 Feb 2026)
  5. TGA, Digital scribes (Last updated 16 Oct 2026)
  6. Avant, AI medical scribes: We answer 10 of the most frequently asked questions (9 Dec 2025)
  7. ASPE, US Department of Health and Human Services, Health Insurance Portability and Accountability Act of 1996 (Publication date 20 Aug 1996)

A useful place to start

Better technology.
Better care, together.

Tell us about your team and what you want to make better. We’ll find a useful place to begin.

Start a conversation